YLYong Jin Lim

Yong Jin Lim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yong Jin Lim has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Bradley L. Urquhart

    Department of Physiology and Pharmacology Western University London Ontario Canada

    3 shared publications
  • Chloe A.K. White

    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada

    2 shared publications
  • Thomas J. Velenosi

    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada

    2 shared publications
  • Andrew S. Kucey

    Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

    1 shared publication
  • Eddie Chan

    London Health Sciences Centre Research Institute, London, ON, Canada; Children's Health Research Institute, London, ON, Canada

    1 shared publication
  • Emily D. Hartjes

    Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

    1 shared publication

Latest Publications

  • Open Access

    The placental transfer of nirmatrelvir using the ex vivo human placental perfusion model

    by Magdalene Zabek, Eddie Chan, Yong Jin Lim, Bradley L. Urquhart, Facundo Garcia‐Bournissen, Janine R. Hutson

    Aims: Nirmatrelvir is an effective therapeutic option for COVID‐19 infection and is often administered after symptom onset in pregnant individuals, but few data are available on the associated fetal exposure. The placental perfusion model evaluates maternal–fetal drug transfer across the human placenta and thus can determine fetal drug exposure. The objective of our study was to quantify the amount of nirmatrelvir transfer across the human placenta using the ex vivo placental perfusion model. Methods: In a dual closed–closed perfusion of a single human placenta lobule, nirmatrelvir was added to the maternal circulation at its clinical concentration (2.21 μg/mL) or at 10 times this level (22.1 μg/mL). For each placenta studied, there was a 1‐h perfusion control period followed by a 3‐h exposure period. Samples of the perfusate were collected throughout the experiment to measure nirmatrelvir concentrations and placental viability markers. Results: Perfusions conducted with nirmatrelvir at 2.21 μg/mL ( n = 4) and 22.1 μg/mL ( n = 5) concentrations showed a fetal–maternal concentration ratio (F:M) of 0.34 and 0.42, respectively, at 180 min. F:M was adjusted for nonplacental physiological factors, including binding of albumin and α‐1‐acid glycoprotein, and ionization. The adjusted F:M ranged from 0.26 to 0.35 for placentas perfused with 2.21 μg/mL and from 0.33 to 0.47 for placentas perfused with 22.1 μg/mL of nirmatrelvir. Conclusions: Nirmatrelvir readily crosses the term human placenta in a concentration‐dependent manner. These transfer kinetics provide a foundation for future physiologically based pharmacokinetic modelling, supporting the development of personalized nirmatrelvir dosing strategies in pregnancy.


  • Open Access

    Characterizing ex vivo models for studying lipid metabolism in triple negative breast cancer

    by Naruenan Wongreantong, Chloe A.K. White, Yong Jin Lim, Karla C. Williams, Thomas J. Velenosi

  • Open Access

    DIATAGeR: Triacylglycerol annotation of data-independent acquisition based lipidomics

    by Victor C.L. Lee, Khanh C.K. Nguyen, Linglan Zhu, Chloe A.K. White, Yong Jin Lim, Tao Huan, Thomas J. Velenosi


  • Open Access

    The impact of progressive chronic kidney disease on hepatic drug metabolism

    by Emily D. Hartjes, Yong Jin Lim, Thomas J. Velenosi, Kait F. Al, Jean M. Macklaim, Andrew S. Kucey, Gregor Reid, Jeremy P. Burton, Gregory B. Gloor, Bradley L. Urquhart


  • Pharmacometabolomics in Drug Disposition, Toxicity, and Precision Medicine

    by George R. Trevor, Yong Jin Lim, Bradley L. Urquhart

    The precision medicine initiative has driven a substantial change in the way scientists and health care practitioners think about diagnosing and treating disease. While it has long been recognized that drug response is determined by the intersection of genetic, environmental and disease factors, improvements in technology have afforded precision medicine guided dosing of drugs to improve efficacy and reduce toxicity. Pharmacometabolomics aims to evaluate small molecule metabolites in plasma and/or urine to help evaluate mechanisms that predict and/or reflect drug efficacy and toxicity. In this mini review, we provide an overview of pharmacometabolomic approaches and methodologies. Relevant examples where metabolomic techniques have been used to better understand drug efficacy and toxicity in major depressive disorder and cancer chemotherapy are discussed. In addition, the utility of metabolomics in drug development and understanding drug metabolism, transport and pharmacokinetics is reviewed. Pharmacometabolomic approaches can help understand factors mediating drug disposition, efficacy and toxicity. While important advancements in this area have been made, their remain several challenges that must be overcome before this approach can be fully implemented into clinical drug therapy. Significance Statement Pharmacometabolomics has emerged as an approach to identify metabolites that allow for implementation of precision medicine approaches to pharmacotherapy. This review article provides an overview pharmacometabolomics including highlights of important examples.